On December 15th, the 4th China Biomedical Industry Chain Innovation and Transformation International Summit and the 4th China Biomedical Industry Chain Innovation Power List Awards Ceremony were jointly hosted by Hangzhou High-tech Zone Government, Yangtze River Delta Data-driven Innovative Biomedical Industry Chain Alliance, and China Biomedical Industry Chain Innovation Transformation Union in Hangzhou. During the conference, Evergreen Therapeutics was recognized as the "Annual Influential Digital Life Health Enterprise of 2023" on the power list for its exceptional contributions to promoting AI clinical practices domestically in recent years.
Conference site
The conference convened both domestic and international academic scientists, research institution leaders, and distinguished corporate executives, including Chen Kai Xian, a member of the Chinese Academy of Sciences; Pan Guangcheng, Senior President of the China Pharmaceutical Industry Association and Deputy Director-General of CBIITA Joint Body; Fu Daxu, President of Shanghai Institute for Biological Sciences; Wei Qiming, a fellow at the American College of Cardiology and American College of Chest Physicians; Zhou Demin, Chairman of the National Key Laboratory Alliance for Pharmacy.
Academician Chen Kaixian delivered a speech
The award has been continuously evaluated for four sessions since its establishment in 2020, always adhering to the purpose of “setting industry benchmarks, inspiring innovative potential, and cultivating an innovative environment”. By utilizing authoritative data analysis from multiple dimensions and verification from various perspectives, it gathers objective data and expert wisdom. The data sources include Pharmacodia Database, Xingye Securities Database, and pharmedcafe Database. Each award ceremony is witnessed by domestic and foreign academicians, leaders of national ministries and commissions, representatives of national academic associations, experts from university research institutes and clinical trial institutions, investment partners as well as executives from listed or soon-to-be-listed companies. The awards cover innovative pharmaceutical enterprises, technology platforms, CROs (Contract Research Organizations), clinical trial institutions，investment institutions，and clinical PIs (Principal Investigators), making it one of the most comprehensive selection awards in the industry. Over 500 industry organizations have participated in the evaluation process throughout previous sessions，making it a benchmark award in the field of innovation and transformation within the biopharmaceutical industry.
Kevin Wang, Chief Business Officer of Evergreen Therapeutics, was present at the award ceremony (positioned sixth from the right).
As one of the few international pharmaceutical companies in China that persistently apply AI technology to enhance the efficiency and success rate of clinical trials, Evergreen Therapeutics has successfully developed 10 pipelines in 4 years, with half of them receiving approval from the US FDA. Moreover, the company has filed over 50 patent applications and obtained more than 20 licenses. Leveraging its self-developed AI platform, Evergreen Therapeutics has achieved a breakthrough in utilizing "reverse transformation science" by integrating genomics and clinical phenotype analysis. This innovative approach utilizes data as the foundation for clinical research and development, establishing a highly efficient model. The company's contributions have been repeatedly acknowledged by government entities, professional institutions, and renowned media outlets. Collaborating with ten digital pharmaceutical companies including Insilico Medicine, XtalPi, and Taimei Medical further exemplifies Evergreen Therapeutic's pivotal role in driving the digital transformation of China's pharmaceutical industry.
